Woteki Catherine E has reported a significant acquisition of shares in Neogen Corp, reflecting her ongoing commitment to the company. This transaction, filed on October 2, 2026, involves both restricted stock units and common stock options. The move is noteworthy as it demonstrates Woteki's confidence in Neogen's future and could impact the company's operational strategies.
Background
Woteki Catherine E is associated with Neogen Corp, a company specializing in in vitro and in vivo diagnostic substances. Neogen trades under the symbol NEOG and is based in Lansing, Michigan. The company is known for its innovative solutions in the life sciences sector, particularly in food safety and animal health. Recent filings indicate that Woteki has been actively involved with the company, with multiple transactions reported over the past year.
What the Filing Says
The recent filing indicates that on October 1, 2026, Woteki acquired 9,804 restricted stock units at a price of $12.24 per share. Additionally, she also obtained the right to buy 20,558 shares of common stock at the same price. Following these transactions, she now owns a total of 28,921 shares directly.
Impact
This acquisition may affect Neogen's strategic direction as Woteki's increased ownership could enhance her influence within the company. As a director, her decisions and insights could shape future initiatives, particularly in the competitive landscape of the life sciences industry.
What's Next
The filing does not say what happens next.